Products for Research Use Only
RegisterLogin

Afuresertib

CAT: 0804-HY-15727-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15727-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Afuresertib (GSK2110183) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with Kis of 0.08/2/2.6 nM for Akt1/Akt2/Akt3, respectively[1][2].
CAS Number
1047644-62-1
Product Name Alternative
GSK2110183; LAE002
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Akt; PKC; ROCK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics; PI3K/Akt/mTOR; Stem Cell/Wnt; TGF-beta/Smad
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Afuresertib.html
Concentration
10mM
Purity
99.53
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1=CC(C2=C(Cl)C=NN2C)=C(Cl)S1)N[C@@H](CC3=CC=CC(F)=C3)CN
Molecular Formula
C18H17Cl2FN4OS
Molecular Weight
427.32
Precautions
H302, H315, H319, H335
References & Citations
[1]Yamaji M, et al. Novel ATP-competitive Akt inhibitor Afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 2017 Nov;6 (11) :2646-2659.|[2]Dumble M, et al. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PLoS One. 2014 Jun 30;9 (6) :e100880
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
Akt1; Akt2; Akt3; PKCβ; PKCη; PKCθ; ROCK
Citation 01
Cancers (Basel) . 2022 May 19;14 (10) :2493.|Cell Syst. 2018 Apr 25;6 (4) :424-443.e7.|Cell. 2024 Feb 1;187 (3) :624-641.e23.|Cold Spring Harb Mol Case Stud. 2022 Jan 10;8 (1) :a006140.|Food Chem Toxicol. 2025 Oct:204:115628.|Genes Dis. 2021 Aug 17;9 (2) :562-575.|Int J Cancer. 2020 Apr 1;146 (7) :1963-1978.|J Biol Chem. 2024 Feb;300 (2) :105641.|J Cell Biochem. 2024 Aug;125 (8) :e30613.|J Physiol. 2017 Jul 1;595 (13) :4207-4225.|Methods Mol Biol. 2018:1711:351-398.|Molecules. 2019 Apr 1;24 (7) :1260.|Research Square Print. October 27th, 2022.|Sci Transl Med. 2021 Jan 27;13 (578) :eaba7308.|Theranostics. 2019 Jan 30;9 (4) :1096-1114.|Biomed Pharmacother. 2025 Nov:192:118707. |bioRxiv. 2025 Jun 16.|Patent. US20230147129A1.

Alternative Products

CatalogName
B4811-5Afuresertib
T7885-01Afuresertib hydrochloride
MBS384821-01Afuresertib HCl
C12749-01Afuresertib (GSK2110183)
A16392-500Afuresertib 500mg
A16392-10Afuresertib 10mg

Popular Products